Loading...

Novo Nordisk A/S

NONOFPNK
Healthcare
Biotechnology
$73.58
$-0.74(-0.99%)

Novo Nordisk A/S NONOF Peers

See (NONOF) competitors and their performances in Stock Market.

Peer Comparison Table: Biotechnology Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
NONOF$73.58-0.99%326.7B20.33$3.62+2.25%
CSLLY$77.85-1.44%150.8B28.62$2.72+1.70%
CMXHF$148.56N/A71.9B27.21$5.46+1.86%
UCBJF$188.94+1.42%35.9B29.99$6.30+0.85%
ARGNF$586.55N/A35.8B35.72$16.42N/A
UCBJY$90.89+2.12%34.6B28.76$3.16+0.87%
ODTC$22,005.00+29.44%24.1B-0.08-$268,995.00N/A
IVBXF$9.74N/A16.1B-973.95-$0.01N/A
WXIBF$3.25N/A13.2B29.55$0.11N/A
GNMSF$211.09-0.19%13B12.38$17.05N/A
Showing 1 to 10 of 100 results
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

NONOF vs CSLLY Comparison

NONOF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NONOF stands at 326.7B. In comparison, CSLLY has a market cap of 150.8B. Regarding current trading prices, NONOF is priced at $73.58, while CSLLY trades at $77.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NONOF currently has a P/E ratio of 20.33, whereas CSLLY's P/E ratio is 28.62. In terms of profitability, NONOF's ROE is +0.81%, compared to CSLLY's ROE of +0.26%. Regarding short-term risk, NONOF is more volatile compared to CSLLY. This indicates potentially higher risk in terms of short-term price fluctuations for NONOF.

Stock Price Comparison

Loading...

Frequently Asked Questions

;